BeyondSpring Competitors and Similar CompaniesClear all

Omeros's competitors and similar companies include Athersys and Otonomy.

	Omeros Omeros Corporation is a biopharmaceutical company developing products focused on inflammation and central nervous system disorders as well as immune-related diseases, including cancers.	Athersys Athersys, a biopharmaceutical company, discovers and develops therapeutic products for the treatment of several disease indications.	Otonomy Otonomy is a biopharmaceutical company developing and commercializing treatments for diseases of the inner and middle ear.
Founding Date	Founding Date 1994	Founding Date 1995	Founding Date 2008
Type	Type Public	Type Public	Type Public
Tags	Tags Healthcare biotech drug development oncology pharma	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development pharma
Locations	Locations Seattle, US HQ	Locations Cleveland, US HQ Canton, US	Locations San Diego, US HQ
Employees	Employees 1968% decrease	Employees 8311% increase	Employees 49
Valuation ($)	Valuation ($) 248.6 m	Valuation ($) 6.3 m	Valuation ($) 5.3 m
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) $5.3m (FY, 2022)	Revenue (est.) $125k (FY, 2021)
Net income	Net income ($3.4m) (FY, 2025)	Net income ($72.5m) (FY, 2022)	Net income ($51.2m) (FY, 2021)
Operating ⚠
Patents (US)	Patents (US) 80 (FY, 2021)	Patents (US) 21 (FY, 2016)	Patents (US) N/A
Patents Issued	Patents Issued N/A	Patents Issued 200 (FY, 2016)	Patents Issued 88 (FY, 2016)
Phase I Trials Products	Phase I Trials Products 3 (FY, 2021)	Phase I Trials Products N/A	Phase I Trials Products 1 (FY, 2016)
Phase II Trials Products	Phase II Trials Products 2 (FY, 2021)	Phase II Trials Products N/A	Phase II Trials Products 2 (FY, 2016)
Phase III Trials Products	Phase III Trials Products 2 (FY, 2021)	Phase III Trials Products N/A	Phase III Trials Products 2 (FY, 2016)
Funding
Total funding raised	Total funding raised $ 354.8m	Total funding raised $ 9m	Total funding raised $ 153.4m